Company News
Cipla Qilu Partnership US Pembrolizumab Biosimilar
Cipla's subsidiary Invagen enters exclusive US licensing deal with Qilu Pharmaceutical for biosimilar QL2107 to Keytruda®.
Qilu handles development and supply; Cipla USA leads commercialization levera
